SCHEMBL2228862

SCHEMBL2228862

O=C(NCc1cccc(CN2CCCC2)c1)c1ccc2c(Cl)c3c(nc2c1)CCCC3

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.68
TP53 P04637 2/20 0.68
KMT2A Q03164 4/20 0.67
MEN1 O00255 3/20 0.67
USP7 Q93009 3/20 0.67
SMN1; SMN2 Q16637 3/20 0.67
GAA P10253 1/20 0.67
GFER P55789 1/20 0.67
ALDH1A1 P00352 2/20 0.66
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
HTT P42858 2/20 0.55
KDM4E B2RXH2 1/20 0.54
MAPK1 P28482 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54
HPGD P15428 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2228771 0.94 MAPT (0.77) MAPTTP53KMT2AMEN1USP7
SCHEMBL2226630 0.88 USP7 (0.87) MAPTTP53KMT2AMEN1USP7
SCHEMBL2228184 0.82 KMT2A (0.60) MAPTTP53KMT2AMEN1USP7
SCHEMBL2219299 0.82 MAPT (0.58) MAPTTP53KMT2AMEN1USP7
SCHEMBL2227633 0.81 MAPT (0.89) MAPTTP53KMT2AMEN1USP7
SCHEMBL2229536 0.81 MAPT (0.89) MAPTTP53KMT2AMEN1USP7
SCHEMBL13822374 0.81 MAPT (0.89) MAPTTP53KMT2AMEN1USP7
SCHEMBL2219175 0.81 KMT2A (1.00) MAPTTP53KMT2AMEN1USP7
SCHEMBL22480054 0.80 USP7 (1.00) MAPTTP53KMT2AMEN1USP7
SCHEMBL2225718 0.77 KMT2A (0.62) MAPTTP53KMT2AMEN1USP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US claimed
US-9328093-B2 Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications HYBRIGENICS SA (FR) 2016-05-03 US disclosed
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2015-03-12 US disclosed
EP-2523938-B1 Amidoacridine derivatives useful as selective inhibitors of ubiquitin specific protease 7 HYBRIGENICS SA (FR) 2014-09-03 EP disclosed
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS HYBRIGENICS SA (FR) 2013-01-24 US disclosed
EP-2523938-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 Hybrigenics S.A. (FR) 2012-11-21 EP disclosed
WO-2011086178-A1 AMIDOACRIDINE DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7 HYBRIGENICS SA (FR) 2011-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130023521-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 MAPT 704/4885TP53 330/4885KMT2A 2349/4885
US-20150072973-A1 NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS USP7, SENP7, PSMA7 MAPT 704/4885TP53 330/4885KMT2A 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.